New drug helps kids with rare immune disease reach Life-Saving transplant
NCT ID NCT02472054
First seen Apr 03, 2026 · Last updated Apr 23, 2026 · Updated 3 times
Summary
This study tested a drug called alemtuzumab as the first treatment for children with a rare, severe immune disorder called hemophagocytic lymphohistiocytosis (HLH). The goal was to see if the drug could keep patients alive long enough to receive a stem cell transplant, which is the only potential long-term control. The study included 29 children and measured how many survived to transplant and how many achieved complete remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Necker-Enfants Malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.